News & Presentations

TellDx-Enabled Circulating Tumor Cell Analysis Predicts Response to DLL3-Targeted Therapy in Small Cell Lung Cancer

Press Release - January 14, 2026

Read More

Tellbio’s Technology Demonstrates that Analysis of Circulating Tumor Cells Can Predict Survival Among Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Radium-223

Press Release - March 27, 2024

Read More

TellBio Announces Consecutive Manuscripts Showcasing Promising Translational and Clinical Applications of the TellDx Platform in Prostate Cancer and Tailoring Therapy in Advanced Breast Cancer

Press Release - July 6, 2023

Read More

Circulating Tumor Cells Isolated with Unique TellDx Technology May Help Predict Response to Therapy in Patients with Progressive Metastatic Breast Cancer

Press Release - May 22, 2023

Read More

Isolation of Circulating Tumor Cells with TellDx Platform Reveals Potential Mechanism of Resistance to Immune Checkpoint Blockade in Melanoma

Press Release - March 16, 2023

Read More

Reduction in Circulating Tumor Cells (CTC), Enriched by TellBio Platform, with Novel Dual-Cadherin Antibody (23C6) Results in Significant Metastasis Suppression

Press Release - October 24, 2022

Read More

Circulating Tumor Cell (CTC) Isolation with TellDx Technology Could Inform Personalized Drug Treatment in Prostate Cancer

Press Release - January 20, 2022

Read More

TellBio’s Scientific Founders Publish Very High Concordance between CTCs and ctDNA from Liquid Biopsies in Patients with Breast Cancer

Press Release - July 15, 2021

Read More

TellBio Unveils Next-Generation Liquid Biopsy Platform Focused on Early Detection and Treatment of Cancer

Press Release - May 10, 2021

Read More